Michael James Newman

CIK: 0001876315

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

INDP

Indaptus Therapeutics, Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (2 total)

INDP
Indaptus Therapeutics, Inc.
Dec 22, 2025
Award(A)
Direct
52.2K shares at avg. $2.03$106K
INDP
Indaptus Therapeutics, Inc.
Oct 9, 2024
Award(A)
Stock Option (Right to Buy)
Direct
75K shares-

		Type	Shares	Price		Ownership
Dec 22, 2025	INDP Indaptus Therapeutics, Inc.	Award(A)	52,204	$2.03	$105,974	Direct
Oct 9, 2024	INDP Indaptus Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	75,000	-	-	Direct

1-2 of 2 transactions

About Newman Michael James

Newman Michael James (SEC CIK 0001876315) files insider reports with the SEC as CSO and Director of Indaptus Therapeutics, Inc. (INDP).

Signal8 holds 2 ownership filings by Newman Michael James, all Form 4s, filed between Oct 10, 2024 and Dec 29, 2025. Those filings report 2 transactions, from Oct 9, 2024 to Dec 22, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Newman Michael James's filings is in NEW YORK, NY.

Recent filings by Newman Michael James

Dec 22, 2025: Grant or award of INDP shares (Form 4, code A).
Oct 9, 2024: Grant or award of INDP derivative securities (Form 4, code A).

Other insiders filing for Indaptus Therapeutics, Inc. (INDP)

Lu Qinglai, Director
Yao Yun, 10% Owner
SINO LION VENTURES Ltd, 10% Owner
Dai Junyi, Chief Executive Officer
Lazar David E., Director
Jabbour Jerome D, Director

How to read Form 4 transaction codes